* Announces that its partner Exelixis obtained FDA
approval of CABOMETYX (cabozantinib) tablets for patients with
advanced renal cell carcinoma who have received prior
anti-angiogenic therapy
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
No comments:
Post a Comment